Abstract | OBJECTIVE: METHODS: We set up a cross-sectional study among healthy postmenopausal women aged 45 to 70 years. The impact of activated protein C (APC) on endogenous thrombin potential was investigated in the plasma samples of 108 women who did not use any hormone therapy (n = 40) or who were treated with transdermal estrogens combined with micronized progesterone ( n = 30) or norpregnane derivatives (n = 38). RESULTS: CONCLUSIONS: Transdermal estrogens combined with norpregnanes may induce APC resistance and activate blood coagulation. These results provide a biological support to epidemiological data regarding the potential thrombogenic effects of norpregnanes. However, these findings need to be confirmed in a randomized trial.
|
Authors | Marianne Canonico, Martine Alhenc-Gelas, Geneviève Plu-Bureau, Valérie Olié, Pierre-Yves Scarabin |
Journal | Menopause (New York, N.Y.)
(Menopause)
2010 Nov-Dec
Vol. 17
Issue 6
Pg. 1122-7
ISSN: 1530-0374 [Electronic] United States |
PMID | 20613675
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Estrogens
- Norpregnanes
- Peptide Fragments
- Progestins
- prothrombin fragment 1.2
- Prothrombin
- Thrombin
|
Topics |
- Activated Protein C Resistance
(blood, etiology)
- Administration, Cutaneous
- Aged
- Cross-Sectional Studies
- Drug Therapy, Combination
- Estrogen Replacement Therapy
(adverse effects)
- Estrogens
(administration & dosage, adverse effects)
- Female
- Hemostasis
(drug effects)
- Humans
- Linear Models
- Middle Aged
- Norpregnanes
(administration & dosage, adverse effects)
- Peptide Fragments
(blood, drug effects)
- Postmenopause
(blood)
- Progestins
(administration & dosage, adverse effects)
- Prothrombin
(drug effects)
- Thrombin
(biosynthesis, drug effects)
|